<p>隨着全球市場面臨對人工智能估值和經濟不確定性的擔憂，亞洲市場也反映出這種謹慎情緒，尤其是在中國，投資者對人工智能相關股票的高估值感到擔憂，抑制了風險偏好。在這樣的環境下，識別被低估的股票可以成為投資者利用潛在市場低效的戰略方法。</p>
<h3>基於現金流的亞洲十大被低估股票</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>當前價格</strong></td>
<td><strong>公允價值（估計）</strong></td>
<td><strong>折扣（估計）</strong></td>
</tr>
<tr>
<td>西安國際醫療投資（SZSE:000516）</td>
<td>CN¥4.76</td>
<td>CN¥9.38</td>
<td>49.3%</td>
</tr>
<tr>
<td>盛達資源有限公司（SZSE:000603）</td>
<td>CN¥25.16</td>
<td>CN¥49.94</td>
<td>49.6%</td>
</tr>
<tr>
<td>PharmaResearch（KOSDAQ:A214450）</td>
<td>₩442500.00</td>
<td>₩870185.20</td>
<td>49.1%</td>
</tr>
<tr>
<td>寧夏建材集團有限公司（SHSE:600449）</td>
<td>CN¥13.11</td>
<td>CN¥26.01</td>
<td>49.6%</td>
</tr>
<tr>
<td>新西蘭國王三文魚投資（NZSE:NZK）</td>
<td>NZ$0.196</td>
<td>NZ$0.39</td>
<td>49.2%</td>
</tr>
<tr>
<td>聯創電子科技有限公司（SZSE:002036）</td>
<td>CN¥10.25</td>
<td>CN¥20.17</td>
<td>49.2%</td>
</tr>
<tr>
<td>JINS HOLDINGS（TSE:3046）</td>
<td>¥6260.00</td>
<td>¥12344.48</td>
<td>49.3%</td>
</tr>
<tr>
<td>EROAD（NZSE:ERD）</td>
<td>NZ$1.50</td>
<td>NZ$2.95</td>
<td>49.1%</td>
</tr>
<tr>
<td>中國儒意控股（SEHK:136）</td>
<td>HK$2.42</td>
<td>HK$4.81</td>
<td>49.7%</td>
</tr>
<tr>
<td>北京小米科技（SHSE:688169）</td>
<td>CN¥153.30</td>
<td>CN¥300.82</td>
<td>49%</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們基於現金流的 277 只被低估亞洲股票的完整列表。</p>
<p>我們將查看我們篩選工具中的一些最佳選擇。</p>
<h2>三養食品（KOSE:A003230）</h2>
<p><strong>概述：</strong> 三養食品有限公司及其子公司在韓國國內和國際上從事食品行業，市值為₩10.86 億。</p>
<p><strong>運營：</strong> 抱歉，但提供的文本中似乎缺少收入細分的詳細信息。如果您有該信息，我可以幫助您總結。</p>
<p><strong>公允價值的估計折扣：</strong> 48%</p>
<p>三養食品的交易價格為₩146 萬，遠低於其估計的公允價值₩280 萬，表明其可能被低估。預計年收益增長 27.52%，年收入增長 22.3%，儘管與韓國市場相比，公司的收益增長較慢，但顯示出強勁的增長潛力。最近在美國的合作，如與 bb.q Chicken 的合作，可能增強其全球品牌影響力和收入來源。</p>
<ul>
<li>我們的三養食品增長報告中的分析暗示未來財務表現強勁。</li>
<li>點擊這裏訪問我們的完整資產負債表健康報告，以瞭解三養食品的動態。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2b15e1a9-ba91-45fe-8ad8-5c94a8b4f210/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2b15e1a9-ba91-45fe-8ad8-5c94a8b4f210/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>KOSE:A003230 截至 2025 年 11 月的折現現金流</p>
<h2>中國儒意控股（SEHK:136）</h2>
<p><strong>概述：</strong> 中國儒意控股有限公司是一家投資控股公司，涉及內容製作和在線流媒體業務，覆蓋中國大陸、香港、歐洲及國際市場，市值為 HK$396.9 億。</p>
<p><strong>運營：</strong> 公司的收入主要來自其內容製作業務，產生了 CN¥648.86 百萬，以及其在線流媒體和在線遊戲業務，共同貢獻了 CN¥34.4 億。</p>
<p><strong>公允價值的估計折扣：</strong> 49.7%</p>
<p>中國儒意控股的交易價格為 HK$2.42，遠低於其估計的公允價值 HK$4.81，表明基於現金流的潛在低估。預計年收益增長 25.54%，超過香港市場 11.6% 的增長率。儘管最近股東稀釋，分析師一致認為潛在價格上漲 72.5%。然而，預計三年的股本回報率仍然温和，為 11.9%。</p>
<ul>
<li>我們編制的增長報告表明，中國儒意控股的未來前景可能向好。</li>
<li>在這份財務健康報告中解鎖我們對中國儒意控股股票分析的全面見解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/61eac35f-fc48-4ef8-bdb9-bb54aa35a2a7/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/61eac35f-fc48-4ef8-bdb9-bb54aa35a2a7/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>SEHK:136 截至 2025 年 11 月的折現現金流</p>
<h2>榮昌生物（SEHK:9995）</h2>
<p><strong>概述：</strong> 榮昌生物有限公司是一家生物製藥公司，專注於在中國大陸和美國發現、開發、生產和商業化生物藥物，治療自身免疫、腫瘤和眼科疾病，市值約為 HK$555.4 億。</p>
<p><strong>運營：</strong> 榮昌生物的收入約為 CN¥22.3 億，來自其生物製藥研究、服務、生產和銷售活動。</p>
<p><strong>公允價值的估計折扣：</strong> 17.2%</p>
<p>榮昌生物有限公司報告稱，2025 年前九個月銷售額為 CNY 17.2 億，較去年同期的 CNY 12.1 億有所增長，同時將淨虧損減少至 CNY 5.507 億，低於 CNY 10.7 億。以 HK$90 的價格交易，低於其公允價值估計 HK$108.73，榮昌生物基於現金流被低估，預計未來三年年收入增長 27.4%，股本回報率預期高達 42.6%。</p>
<ul>
<li>我們精心準備的榮昌生物增長報告暗示其未來財務前景可能強於近期結果。</li>
<li>在這裏深入瞭解榮昌生物的完整分析健康報告。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d8925f4e-6869-4d4b-b13c-794198898df9/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d8925f4e-6869-4d4b-b13c-794198898df9/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>SEHK:9995 截至 2025 年 11 月的折現現金流</p>
<h2>抓住機會</h2>
<ul>
<li>點擊此鏈接深入瞭解我們基於現金流的 277 家公司篩選器中的公司。</li>
<li>已經擁有這些公司？通過將您的投資組合與 Simply Wall St 連接，清晰化您的投資決策，您可以輕鬆監控所有股票的關鍵指標。</li>
<li>通過 Simply Wall St 的免費應用程序發現投資機會，獲取各市場無與倫比的股票分析。</li>
</ul>
<h2>尋找新的視角？</h2>
<ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>通過穩健的分紅支付者來多樣化您的投資組合，以提供可靠的收入來源，以應對潛在的市場動盪。</li>
<li>通過顯示強勁增長潛力的公司來充實您的投資組合，這些公司得到了分析師和管理層的樂觀展望支持。</li>
</ul>
<p><em>這篇來自 Simply Wall St 的文章具有一般性。<strong>我們基於歷史數據和分析師預測提供評論，僅使用無偏見的方法，我們的文章不構成財務建議。它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。</strong> 我們旨在為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>

榮昌生物

中國儒意

<p>亞洲市場面臨人工智能估值擔憂，投資者開始尋求被低估的股票。值得關注的股票包括三養食品、中國儒意控股和榮昌生物，這些股票的交易價格均低於估計的公允價值。三養食品與美國的合作顯示出強勁的增長潛力。儘管股東稀釋，中國儒意控股仍被低估，預計價格將上漲。榮昌生物報告了收入增長和淨虧損減少，顯示出未來的財務實力。Simply Wall St 提供投資分析和投資組合管理的工具</p>

<p>As global markets grapple with concerns over AI valuations and economic uncertainties, Asian markets have mirrored this cautious sentiment, particularly in China where investor worries about frothy valuations in AI-focused stocks have dampened risk appetite. In such an environment, identifying undervalued stocks can be a strategic approach for investors looking to capitalize on potential market inefficiencies.</p>
<div class="lb-trans"><p>隨着全球市場面臨對人工智能估值和經濟不確定性的擔憂，亞洲市場也反映出這種謹慎情緒，尤其是在中國，投資者對人工智能相關股票的高估值感到擔憂，抑制了風險偏好。在這樣的環境下，識別被低估的股票可以成為投資者利用潛在市場低效的戰略方法。</p>
</div><h3>Top 10 Undervalued Stocks Based On Cash Flows In Asia</h3>
<div class="lb-trans"><h3>基於現金流的亞洲十大被低估股票</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Current Price</strong></td>
<td><strong>Fair Value (Est)</strong></td>
<td><strong>Discount (Est)</strong></td>
</tr>
<tr>
<td>Xi'an International Medical Investment (SZSE:000516)</td>
<td>CN¥4.76</td>
<td>CN¥9.38</td>
<td>49.3%</td>
</tr>
<tr>
<td>Shengda ResourcesLtd (SZSE:000603)</td>
<td>CN¥25.16</td>
<td>CN¥49.94</td>
<td>49.6%</td>
</tr>
<tr>
<td>PharmaResearch (KOSDAQ:A214450)</td>
<td>₩442500.00</td>
<td>₩870185.20</td>
<td>49.1%</td>
</tr>
<tr>
<td>Ningxia Building Materials GroupLtd (SHSE:600449)</td>
<td>CN¥13.11</td>
<td>CN¥26.01</td>
<td>49.6%</td>
</tr>
<tr>
<td>New Zealand King Salmon Investments (NZSE:NZK)</td>
<td>NZ$0.196</td>
<td>NZ$0.39</td>
<td>49.2%</td>
</tr>
<tr>
<td>LianChuang Electronic TechnologyLtd (SZSE:002036)</td>
<td>CN¥10.25</td>
<td>CN¥20.17</td>
<td>49.2%</td>
</tr>
<tr>
<td>JINS HOLDINGS (TSE:3046)</td>
<td>¥6260.00</td>
<td>¥12344.48</td>
<td>49.3%</td>
</tr>
<tr>
<td>EROAD (NZSE:ERD)</td>
<td>NZ$1.50</td>
<td>NZ$2.95</td>
<td>49.1%</td>
</tr>
<tr>
<td>China Ruyi Holdings (SEHK:136)</td>
<td>HK$2.42</td>
<td>HK$4.81</td>
<td>49.7%</td>
</tr>
<tr>
<td>Beijing Roborock Technology (SHSE:688169)</td>
<td>CN¥153.30</td>
<td>CN¥300.82</td>
<td>49%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>當前價格</strong></td>
<td><strong>公允價值（估計）</strong></td>
<td><strong>折扣（估計）</strong></td>
</tr>
<tr>
<td>西安國際醫療投資（SZSE:000516）</td>
<td>CN¥4.76</td>
<td>CN¥9.38</td>
<td>49.3%</td>
</tr>
<tr>
<td>盛達資源有限公司（SZSE:000603）</td>
<td>CN¥25.16</td>
<td>CN¥49.94</td>
<td>49.6%</td>
</tr>
<tr>
<td>PharmaResearch（KOSDAQ:A214450）</td>
<td>₩442500.00</td>
<td>₩870185.20</td>
<td>49.1%</td>
</tr>
<tr>
<td>寧夏建材集團有限公司（SHSE:600449）</td>
<td>CN¥13.11</td>
<td>CN¥26.01</td>
<td>49.6%</td>
</tr>
<tr>
<td>新西蘭國王三文魚投資（NZSE:NZK）</td>
<td>NZ$0.196</td>
<td>NZ$0.39</td>
<td>49.2%</td>
</tr>
<tr>
<td>聯創電子科技有限公司（SZSE:002036）</td>
<td>CN¥10.25</td>
<td>CN¥20.17</td>
<td>49.2%</td>
</tr>
<tr>
<td>JINS HOLDINGS（TSE:3046）</td>
<td>¥6260.00</td>
<td>¥12344.48</td>
<td>49.3%</td>
</tr>
<tr>
<td>EROAD（NZSE:ERD）</td>
<td>NZ$1.50</td>
<td>NZ$2.95</td>
<td>49.1%</td>
</tr>
<tr>
<td>中國儒意控股（SEHK:136）</td>
<td>HK$2.42</td>
<td>HK$4.81</td>
<td>49.7%</td>
</tr>
<tr>
<td>北京小米科技（SHSE:688169）</td>
<td>CN¥153.30</td>
<td>CN¥300.82</td>
<td>49%</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 277 stocks from our Undervalued Asian Stocks Based On Cash Flows screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們基於現金流的 277 只被低估亞洲股票的完整列表。</p>
</div><p>We're going to check out a few of the best picks from our screener tool.</p>
<div class="lb-trans"><p>我們將查看我們篩選工具中的一些最佳選擇。</p>
</div><h2>Samyang Foods (KOSE:A003230)</h2>
<div class="lb-trans"><h2>三養食品（KOSE:A003230）</h2>
</div><p><strong>Overview:</strong> Samyang Foods Co., Ltd., along with its subsidiaries, operates in the food industry both domestically in South Korea and internationally, with a market cap of ₩10.86 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 三養食品有限公司及其子公司在韓國國內和國際上從事食品行業，市值為₩10.86 億。</p>
</div><p><strong>Operations:</strong> I'm sorry, but it appears that the revenue segment details are missing from the provided text. If you have that information, I can help summarize it for you.</p>
<div class="lb-trans"><p><strong>運營：</strong> 抱歉，但提供的文本中似乎缺少收入細分的詳細信息。如果您有該信息，我可以幫助您總結。</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 48%</p>
<div class="lb-trans"><p><strong>公允價值的估計折扣：</strong> 48%</p>
</div><p>Samyang Foods is trading at ₩1.46 million, significantly below its estimated fair value of ₩2.8 million, suggesting it may be undervalued based on cash flows. With earnings forecasted to grow 27.52% annually and revenue expected to increase by 22.3% per year, the company shows strong growth potential despite slower earnings growth compared to the Korean market. Recent collaborations in the U.S., like with bb.q Chicken, could enhance its global brand presence and revenue streams.</p>
<div class="lb-trans"><p>三養食品的交易價格為₩146 萬，遠低於其估計的公允價值₩280 萬，表明其可能被低估。預計年收益增長 27.52%，年收入增長 22.3%，儘管與韓國市場相比，公司的收益增長較慢，但顯示出強勁的增長潛力。最近在美國的合作，如與 bb.q Chicken 的合作，可能增強其全球品牌影響力和收入來源。</p>
</div><ul>
<li>The analysis detailed in our Samyang Foods growth report hints at robust future financial performance.</li>
<li>Click here and access our complete balance sheet health report to understand the dynamics of Samyang Foods.</li>
</ul>
<div class="lb-trans"><ul>
<li>我們的三養食品增長報告中的分析暗示未來財務表現強勁。</li>
<li>點擊這裏訪問我們的完整資產負債表健康報告，以瞭解三養食品的動態。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2b15e1a9-ba91-45fe-8ad8-5c94a8b4f210/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/2b15e1a9-ba91-45fe-8ad8-5c94a8b4f210/chart/dcf?theme=light"/></p>
<p>KOSE:A003230 Discounted Cash Flow as at Nov 2025</p>
<div class="lb-trans"><p>KOSE:A003230 截至 2025 年 11 月的折現現金流</p>
</div><h2>China Ruyi Holdings (SEHK:136)</h2>
<div class="lb-trans"><h2>中國儒意控股（SEHK:136）</h2>
</div><p><strong>Overview:</strong> China Ruyi Holdings Limited is an investment holding company involved in content production and online streaming across Mainland China, Hong Kong, Europe, and internationally with a market cap of HK$39.69 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 中國儒意控股有限公司是一家投資控股公司，涉及內容製作和在線流媒體業務，覆蓋中國大陸、香港、歐洲及國際市場，市值為 HK$396.9 億。</p>
</div><p><strong>Operations:</strong> The company's revenue is primarily derived from its content production business, which generated CN¥648.86 million, and its online streaming and online gaming businesses, which together contributed CN¥3.44 billion.</p>
<div class="lb-trans"><p><strong>運營：</strong> 公司的收入主要來自其內容製作業務，產生了 CN¥648.86 百萬，以及其在線流媒體和在線遊戲業務，共同貢獻了 CN¥34.4 億。</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 49.7%</p>
<div class="lb-trans"><p><strong>公允價值的估計折扣：</strong> 49.7%</p>
</div><p>China Ruyi Holdings is trading at HK$2.42, well below its estimated fair value of HK$4.81, indicating potential undervaluation based on cash flows. Earnings are projected to grow 25.54% annually, outpacing the Hong Kong market's growth rate of 11.6%. Despite recent shareholder dilution, analysts agree on a potential price increase of 72.5%. However, the forecasted return on equity remains modest at 11.9% over three years.</p>
<div class="lb-trans"><p>中國儒意控股的交易價格為 HK$2.42，遠低於其估計的公允價值 HK$4.81，表明基於現金流的潛在低估。預計年收益增長 25.54%，超過香港市場 11.6% 的增長率。儘管最近股東稀釋，分析師一致認為潛在價格上漲 72.5%。然而，預計三年的股本回報率仍然温和，為 11.9%。</p>
</div><ul>
<li>The growth report we've compiled suggests that China Ruyi Holdings' future prospects could be on the up.</li>
<li>Unlock comprehensive insights into our analysis of China Ruyi Holdings stock in this financial health report.</li>
</ul>
<div class="lb-trans"><ul>
<li>我們編制的增長報告表明，中國儒意控股的未來前景可能向好。</li>
<li>在這份財務健康報告中解鎖我們對中國儒意控股股票分析的全面見解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/61eac35f-fc48-4ef8-bdb9-bb54aa35a2a7/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/61eac35f-fc48-4ef8-bdb9-bb54aa35a2a7/chart/dcf?theme=light"/></p>
<p>SEHK:136 Discounted Cash Flow as at Nov 2025</p>
<div class="lb-trans"><p>SEHK:136 截至 2025 年 11 月的折現現金流</p>
</div><h2>RemeGen (SEHK:9995)</h2>
<div class="lb-trans"><h2>榮昌生物（SEHK:9995）</h2>
</div><p><strong>Overview:</strong> RemeGen Co., Ltd. is a biopharmaceutical company that focuses on discovering, developing, producing, and commercializing biological drugs for autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States, with a market cap of approximately HK$55.54 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 榮昌生物有限公司是一家生物製藥公司，專注於在中國大陸和美國發現、開發、生產和商業化生物藥物，治療自身免疫、腫瘤和眼科疾病，市值約為 HK$555.4 億。</p>
</div><p><strong>Operations:</strong> RemeGen generates revenue of approximately CN¥2.23 billion from its biopharmaceutical research, service, production, and sales activities.</p>
<div class="lb-trans"><p><strong>運營：</strong> 榮昌生物的收入約為 CN¥22.3 億，來自其生物製藥研究、服務、生產和銷售活動。</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 17.2%</p>
<div class="lb-trans"><p><strong>公允價值的估計折扣：</strong> 17.2%</p>
</div><p>RemeGen Co., Ltd. reported CNY 1.72 billion in sales for the first nine months of 2025, up from CNY 1.21 billion a year earlier, while reducing its net loss to CNY 550.7 million from CNY 1.07 billion. Trading at HK$90, below its fair value estimate of HK$108.73, RemeGen is undervalued based on cash flows with expected revenue growth of 27.4% annually over the next three years and a high forecasted return on equity of 42.6%.</p>
<div class="lb-trans"><p>榮昌生物有限公司報告稱，2025 年前九個月銷售額為 CNY 17.2 億，較去年同期的 CNY 12.1 億有所增長，同時將淨虧損減少至 CNY 5.507 億，低於 CNY 10.7 億。以 HK$90 的價格交易，低於其公允價值估計 HK$108.73，榮昌生物基於現金流被低估，預計未來三年年收入增長 27.4%，股本回報率預期高達 42.6%。</p>
</div><ul>
<li>Our expertly prepared growth report on RemeGen implies its future financial outlook may be stronger than recent results.</li>
<li>Delve into the full analysis health report here for a deeper understanding of RemeGen.</li>
</ul>
<div class="lb-trans"><ul>
<li>我們精心準備的榮昌生物增長報告暗示其未來財務前景可能強於近期結果。</li>
<li>在這裏深入瞭解榮昌生物的完整分析健康報告。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d8925f4e-6869-4d4b-b13c-794198898df9/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/d8925f4e-6869-4d4b-b13c-794198898df9/chart/dcf?theme=light"/></p>
<p>SEHK:9995 Discounted Cash Flow as at Nov 2025</p>
<div class="lb-trans"><p>SEHK:9995 截至 2025 年 11 月的折現現金流</p>
</div><h2>Seize The Opportunity</h2>
<div class="lb-trans"><h2>抓住機會</h2>
</div><ul>
<li>Click this link to deep-dive into the 277 companies within our Undervalued Asian Stocks Based On Cash Flows screener.</li>
<li>Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.</li>
<li>Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊此鏈接深入瞭解我們基於現金流的 277 家公司篩選器中的公司。</li>
<li>已經擁有這些公司？通過將您的投資組合與 Simply Wall St 連接，清晰化您的投資決策，您可以輕鬆監控所有股票的關鍵指標。</li>
<li>通過 Simply Wall St 的免費應用程序發現投資機會，獲取各市場無與倫比的股票分析。</li>
</ul>
</div><h2>Searching for a Fresh Perspective?</h2>
<div class="lb-trans"><h2>尋找新的視角？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>通過穩健的分紅支付者來多樣化您的投資組合，以提供可靠的收入來源，以應對潛在的市場動盪。</li>
<li>通過顯示強勁增長潛力的公司來充實您的投資組合，這些公司得到了分析師和管理層的樂觀展望支持。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation.</strong> We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>這篇來自 Simply Wall St 的文章具有一般性。<strong>我們基於歷史數據和分析師預測提供評論，僅使用無偏見的方法，我們的文章不構成財務建議。它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。</strong> 我們旨在為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
</div>

亞洲市場價值精選：三隻交易價格低於預估價值的股票